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1  | INTRODUC TION
In	 the	 Netherlands,	 cervical	 intraepithelial	 neoplasia	 (CIN)	 de‐
tection	 rates	 have	 increased	 over	 the	 last	 decade,	 largely	 inde‐
pendent	 of	 the	 socioeconomic	 and	 demographic	 factors.1	 The	
replacement	 of	 conventional	 cytology	 by	 high‐risk	 human	 papil‐







As	 more	 CIN	 lesions	 are	 detected,	 there	 is	 concern	 about	
overtreatment,	which	could	result	 in	 increased	harm	associated	
with	 screening.4	 Evidence	 suggests	 that	 there	 is	 an	 association	
between	 excisional	 treatments	 for	 CIN	 and	 adverse	 obstet‐
ric	 outcomes	 including	 preterm	 birth	 and	 low	 birthweight.5,6 
Increasing	 excision	 volume	 has	 been	 associated	with	 increased	




formation	 zone	 (LLETZ)	 compared	 with	 both	 colposcopy‐only	
and	biopsy‐diagnosed	women.8
The	 Dutch	 Association	 of	 Obstetrics	 and	 Gynecology	 has	
published	 consensus‐based	 guidelines	 for	 CIN	 treatment	 and	
management	which	detail	the	recommended	treatment	practices,	
including	 recommending	 no	 treatment	 of	 CIN	 1	 and	 excisional	
treatment	of	CIN	2+.9	However,	compliance	with	these	guidelines	
has	never	been	evaluated.	The	lack	of	evaluation	of	CIN	manage‐
ment	 in	 the	Dutch	 setting	 has	 been	 recognized	 by	 others4 as a 
knowledge	gap	 in	an	otherwise	closely	monitored	program.	Our	
study	intends	to	objectify	current	clinical	management	of	CIN	to	




2  | MATERIAL AND METHODS
National	organized	 cervical	 cancer	 screening	has	 taken	place	 in	
the	Netherlands	since	the	1980s.	Women	are	invited	for	cytology	
screening	every	5	years	from	the	ages	30	to	60.	Screening	takes	
place	 within	 primary	 care.	Women	 are	 referred	 to	 a	 gynecolo‐
gist	 when	 colposcopy	 is	 required.	 Details	 of	 clinical	 guidelines	
for	 management	 of	 CIN	 are	 given	 in	 Table	1.	 Since	 1998,	 the	
recommendations	 for	 management	 of	 abnormal	 cytology	 have	
been	 fairly	 stable,	 allowing	 for	 more	 reliable	 measurement	 of	
procedural	 parameters	 after	 colposcopy.	 In	 2017,	 hrHPV	 test‐
ing	 replaced	 cytology	 as	 the	 primary	 screening	 test	 within	 the	
program.10
Our	 study	 is	 a	 population‐based	 cohort	 study.	 Women	 aged	
29‐63	years	who	participated	in	the	national	screening	program	and	re‐
ceived	referral	advice	between	1	January	2005	and	31	December	2014	






referrals	 than	 for	 direct	 referrals	 and	 increased	with	 age.	 Large	 excision	 rates	 in‐
creased	with	CIN	diagnosis	severity.









Both	 over‐	 and	 undertreatment	 of	 cervical	 intraepithe‐
lial	 neoplasia	 occurs	 after	 referral	 from	 organized	 cervi‐
cal	 	cancer	screening,	despite	 treatment	guidelines	being	
available.
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•	 Direct	 referrals:	Women	who	 received	 referral	 advice	after	pri‐
mary	 cytology	 of	 high‐grade	 squamous	 intraepithelial	 lesion	
(HSIL)/adenocarcinoma	in	situ	(AIS)/atypical	endometrial	glandu‐





mous	 cells	 of	 undetermined	 significance	 (ASC‐US)/low‐grade	
squamous	intraepithelial	lesion	(LSIL)	or	endocervical	AGC.





We	 excluded	 women	 with	 primary	 smears	 taken	 by	 a	 gy‐
necologist,	 as	 women	 under	 the	 care	 of	 a	 gynecologist	 in	 the	
Netherlands	are	usually	already	receiving	specialist	care.	Indirect	
referrals	 must	 have	 been	 referred	 within	 4	years	 of	 primary	
screening	to	be	 included,	 in	 line	with	the	definitions	used	 in	the	
monitoring	 of	 the	 national	 screening	 program.	 Repeat	 cytology	








a	 nationwide	 coverage	 of	 all	 pathology	 labs.11	Women	 are	 identi‐
fied	by	the	first	eight	letters	of	their	surname	(maiden	name	is	used	
for	married	women)	 and	 date	 of	 birth.	 Information	 about	 primary	
screening	as	well	as	up	to	five	follow‐up	cytology	and/or	histology	
samples	were	 selected.	Follow	up	of	primary	 smears	was	 included	
until	the	end	of	the	database—31	March	2016.	We	defined	“episode	
of	screening”	as	the	period	starting	with	the	primary	screening	test,	



















punch	 biopsy	 (excluding	 cone	 biopsy),	 cytology	 only,	 other	 tech‐
niques.	This	ranking	was	verified	by	gynecologists	and	pathologists.
TA B L E  1  Summary	of	Dutch	CIN	treatment	guidelines
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See‐and‐treat	management	involves	combining	colposcopy	and	
treatment	in	the	same	outpatient	visit.12	A	large	excision	in	the	next	
record	 after	 referral	 was	 considered	 indicative	 of	 see‐and‐treat	








Chi‐square	 tests	 were	 performed	 to	 compare	 differences	 be‐
tween	 proportions.	 Analysis	 of	 variance	 was	 used	 to	 compare	
mean	ages	across	referral	types.	For	one‐way	tables,	a	chi‐square	
goodness	of	fit	test	was	applied.	Confidence	intervals	for	propor‐




We	 used	 a	 retrospective,	 anonymized	 dataset	 from	 PALGA,	
which	is	exempt	from	ethical	approval	by	a	Medical	Ethics	Testing	
Committee.	We	obtained	anonymized	clinical	data	(only	women	












From	 the	 5	450	148	 primary	 cytology	 smears	 taken	 within	 the	












39.9%	 for	 second	 indirect	 referrals	 (Table	2).	When	 restricted	 to	
referrals	that	resulted	in	a	histological	diagnosis	(i.e.	excluding	ep‐
isodes	with	 no	 recorded	 diagnosis	 or	 no	 histology	 taken),	 there	
were	 still	 differences	 in	 the	 proportion	 of	 episodes	 diagnosed	
with	a	CIN	lesion	between	the	referral	groups	(direct:	88.7%;	first	
indirect:	78.1%;	second	 indirect:	67.0%)	and	the	difference	were	
statistically	 significant	 (χ2	 [2,	 n = 72	902]	=	2161.98,	 P < 0.001)	
(figures	not	presented).	Among	direct	referrals,	there	was	a	higher	
proportion	of	women	with	a	CIN	3	diagnosis	(53.5%)	than	among	
indirect	 referrals	 (first	 indirect:	 17.5%;	 second	 indirect:	 8.8%)	
(Table	2).
The	 highest	 proportion	 of	 CIN	 lesions	 were	 diagnosed	 in	
women	 aged	 29‐33	years;	 79.8%	 of	 all	 the	 referrals	 in	 this	 age	
group	were	diagnosed	with	a	CIN	lesion	(Figure	2).	The	proportion	
of	episodes	with	no	recorded	diagnosis	or	no	histology	increased	
Variable Direct referrals First indirect referrals Second indirect referrals P
N % N % N %
Total referrals 44 209 34 282 6 748
Total unique woman IDa  43 827 34 081 6	725
Age
Mean	age 39.16 SD:	8.58 39.54	 SD: 8.49 41.35	 SD: 8.74 < 0.001
29–33 12	452	 28.2% 9 086 26.5% 1	352 20.0% < 0.001
34–38 9 373 21.2% 6 661 19.4% 1 117 16.6%
39–43 8	151 18.4% 6	351 18.5% 1	250 18.5%
44–48 6 027 13.6% 5	448 15.9% 1 196 17.7%
49–53 3 944 8.9% 3	567 10.4% 1	005 14.9%
54–58 2	527 5.7% 2 022 5.9% 513 7.6%
59–63 1	735 3.9% 1 147 3.4% 315 4.7%
Period
2005–2009 20 630 46.7% 14 400 42.0% 2 803 41.5% < 0.001
2010–2014 23	579 53.3% 19 882 58.0% 3	945 58.5%
Highest diagnosis of the episode after referral
No	recorded	diagnosis 1 770 4.0% 1	275 3.7% 835	 12.4% < 0.001
Cytology	only 2 023 4.6% 4	540 13.2% 1 894 28.1%
Benign/Otherb  3 019 6.8% 6 072 17.7% 1 306 19.4%
CIN	1 4 039 9.1% 9 024 26.3% 1 411 20.9%
CIN	2 8	152 18.4% 7 219 21.1% 688 10.2%
CIN	3 23 649 53.5% 5	996 17.5% 594 8.8%







TA B L E  2  Demographic	characteristics	of	women	referred	for	colposcopy	following	participation	in	the	Dutch	cervical	cancer	screening	
program,	all	referral	types,	2005–2014,	rounded	percentages
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with	age	 (Figure	2).	 In	women	aged	44	years	and	older,	61.3%	of	
the	 no	 recorded	 diagnosis	 and	 55.3%	 of	 the	 no	 histology	 group	










CIN I (%) CIN 2 (%) CIN3 (%) P
Direct	referrals
Hysterectomy 1.2 1.8 3.4 <0.001
Large	excisiona  34.4 69.4 82.0
Biopsyb  62.5 28.2 14.3
Other	techniquesc  1.9 0.6 0.3
First	indirect	referrals
Hysterectomy 0.9 1.7 2.9 <0.001
Large	excisiona  23.9 66.9 81.3
Biopsyb  73.2 30.8 15.4
Other	techniquesc  1.9 0.6 0.4
Second	indirect	referral
Hysterectomy 0.6 2.2 1.9 <0.001
Large	excisiona  19.7 61.8 80.3
Biopsyb  77.5 35.3 17.3
Other	techniquesc  2.2 0.7 0.5
All	referrals
Hysterectomy 1.0 1.8 3.3 <0.001
Large	excisiona  26.4 68.0 81.8
Biopsyb  70.7 29.7 14.6




cIncludes	 polypectomy,	 endometrial	 and	 endocervical	 curettage,	 and	 histology	 not	 otherwise	
specified.	
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χ2	(2,	n = 14	474)	=	193.1,	P < 0.001).	No	age‐dependency	was	seen	
in	the	percentage	with	large	excision	treatment	of	CIN	3	(figures	not	
shown).	For	CIN	1	 lesions,	 the	proportion	of	 treatment	with	 large	
excision	increased	with	age.	Rates	of	treatment	with	large	excision	
differed	 significantly	 between	 referral	 types	 across	 all	 age	 groups	
for	CIN	1	lesions	(from	13.1%	to	50.4%)	and	for	the	four	youngest	
age	groups	for	CIN	2+	lesions	(Figure	3).
See‐and‐treat	management	was	 observed	more	 often	 in	 direct	
referrals	than	indirect	referrals	and	was	performed	mostly	in	women	
with	 severe	CIN	 lesions	 (Figure	4).	Treatment	of	CIN	1	or	 lower,	 in	
see‐and‐treat	 management	 increased	 with	 age	 across	 all	 referral	
types	and	were	higher	for	indirect	referrals	in	all	age	groups	(Figure	5).
4  | DISCUSSION
Despite	 recommendations	 not	 to	 treat	 CIN	 1	 lesions,	 we	 found	
that	26.4%	of	the	diagnosed	CIN1	lesions	underwent	an	excisional	






with	 the	 latest	 reporting	 that	16%	of	CIN	1	 lesions	were	 treated	
and	that	there	was	an	increase	in	the	proportion	of	CIN	1	that	was	
not	 treated	between	audit	periods.	However,	 compared	with	 the	
European	 Federation	 for	 Colposcopy	 guidelines16	 that	 state	 that	




viewed	 journals,	 though	 Danish	 researchers	 have	 recommended	
monitoring	of	CIN	treatment	trends	 in	 light	of	the	 increasing	CIN	
treatment	rates	in	Denmark.17
Monitoring	 of	 treatment	 rates	 can	 have	 a	 positive	 effect	 on	
compliance	 with	 guidelines	 by	 making	 practitioners	 cognizant	 of	
recommendations.	A	study	from	one	US	hospital	found	that	active	










ment rates could be even larger.
It	is	unrealistic	to	expect	no	CIN	1	treatment,	as	there	will	always	
be	women	with	persistent	or	recurring	low‐grade	abnormalities	for	
whom	 treatment	may	be	 favorable	 or	 reassuring.19	Guidelines	 are	
only	 one	 factor	 in	 clinical	 decision	making	 for	 CIN;	 gynecologists	
consider	 information	 about	 colposcopy,	 cytology,	 hrHPV	 status,	
family	planning,	age,	women's	preferences	and	other	factors	when	




opsies.	 Additionally,	 in	 women	 with	 transformation	 zone	 type	 3,	
diagnostic	 LLETZ	 after	 high‐grade	 cytology	 is	 indicated	 in	 IARC	
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guidelines.20	 In	 such	 situations,	 performing	 LLETZ	may	be	 a	 justi‐
fiable,	 appropriate	 treatment.	Clarification	of	 a	 reasonable	 rate	 of	




The	treatment	guidelines	were	revised	in	201521 and now advise 





in	 indirect	 referrals	 than	 direct	 referrals,	 and	 increased	 with	 age.	
These	 findings	are	 similar	 to	 those	of	other	Dutch	 studies.24	Given	
the	higher	number	of	CIN	1	and	lower	diagnoses	in	the	two	indirect	
referral	groups,	this	finding	is	unsurprising.	Our	results	are	consistent	

























cordant	 high‐grade	 cytology	 and	 colposcopy	 could	 minimize	 over‐
treatment,	as	could	the	use	of	a	grading	system,	such	as	the	Swede	
score,	which	has	shown	to	have	high	specificity	for	CIN	2+	lesions.25
It	 is	 not	 surprising	 that	 the	 rates	 of	 treatment	with	 large	 exci‐
sion	 for	CIN	2+	 lesions	vary	 little	by	age	within	 referral	 types.	Up	
until	 2015,	 treatment	 guidelines	 for	 CIN	 2	 were	 not	 age‐specific.	
However,	 the	 2015	Guidelines21	 state	 that	women	with	CIN	2	 le‐
sions	should	be	individually	assessed	as	to	whether	the	benefits	of	
treatment	outweigh	the	risks,	largely	related	to	future	childbearing.	
Active	 surveillance	of	 young	women	allows	 time	 for	CIN	2	 lesions	
to	regress,	which	is	likely	to	occur	in	most	CIN	2	cases.26	However,	
















due	 to	 data	 issues,	 such	 as	 records	 belonging	 to	 one	 woman	 not	




in	 an	unethical	 study	 in	which	 treatment	was	delayed	or	withheld	
from	women	with	high‐grade	lesions	showed	that	the	cumulative	in‐
cidence	of	 cervical	 or	 vaginal	 vault	 cancer	was	31.3%	at	30	years,	
with	a	higher	cumulative	incidence	(50.3%)	among	women	with	per‐
sistent	high‐grade	lesions.27	Timely	and	effective	treatment	of	CIN	




Our	study	 is	 the	 first	 to	use	a	national	database	 to	 investigate	
CIN	 treatment	practices	 in	 the	Netherlands.	Analysis	 in	 this	 study	











analyze	 by	 depth	 of	 excision	 or	 lesion	 size.	 This	 is	 not	 coded	 in	







Validation	 of	 our	 results	 with	 clinical	 data	 found	 that	 PALGA	
may	slightly	overestimate	CIN	1	treatments	(Appendix	S2),	although	
these	 clinical	 data	 came	 from	 a	 highly	 specialized	 clinic	with	 phy‐
sicians	 who	 almost	 exclusively	 treat	 cervical	 dysplasia.	 As	 such,	
treatment	of	CIN	1	with	excision	at	this	clinic	is	likely	to	occur	less	
often	than	the	average.	One	Dutch	study	compared	the	 impact	of	
different	 CIN	 management	 strategies	 (more‐or‐less	 aggressive)	 in	
two	hospital	facilities	in	the	same	city	and	found	that	68%	fewer	CIN	
1	lesions	were	found	with	the	less	aggressive	strategy.30	As	PALGA	






it	 is	 possible	 that	 follow	up	was	 censored	 early	 for	 some	women,	








to	 them.	This	may	 lead	 to	greater	 compliance	with	 the	guidelines,	
reducing	potential	harm	to	women	referred	from	screening.
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